Understand · Sex + Relationships
The short answer on vaginal estrogen after breast cancer
Low-dose vaginal estrogen may be an option for some women after breast cancer, but it's a decision to make with your oncologist. Gynecologists recommend trying nonhormonal products first. If those don't work, guidance says vaginal estrogen may be used after weighing the risks, including by women on tamoxifen. For women on aromatase inhibitors there's more caution, and the decision should involve both the gynecologist and the oncologist.
What to know about vaginal estrogen after breast cancer
- Try nonhormonal options first. Lubricants and moisturizers come before any hormone.
- Your treatment matters. Tamoxifen and aromatase inhibitors are treated differently.
- The evidence so far is reassuring. A 2024 study of more than 49,000 women found no rise in breast cancer deaths with vaginal estrogen.
- Menopause pills and patches are different. Systemic hormone therapy is generally not recommended after breast cancer.
Part of Babette's series on sex after breast cancer. For nonhormonal options, see What Helps Vaginal Dryness After Breast Cancer?
What is low-dose vaginal estrogen?
It's estrogen that treats the vaginal tissue directly, as a cream, tablet, insert or ring, at a much lower dose than menopause pills or patches. The American Cancer Society (ACS) says little of it reaches the bloodstream, and that anyone with concerns should ask their team why it's considered safe for them.
Can you use vaginal estrogen if you take tamoxifen or an aromatase inhibitor?
The American College of Obstetricians and Gynecologists (ACOG) says that if nonhormonal treatment hasn't worked, low-dose vaginal estrogen may be used after talking through risks and benefits, including by women taking tamoxifen.
Aromatase inhibitors work by driving estrogen as low as possible, so even small amounts matter more. For women taking one, ACOG says the decision should be shared between the patient, her gynecologist and her oncologist. Presenters at a 2024 National Comprehensive Cancer Network (NCCN) meeting made the same distinction: vaginal estrogen and vaginal DHEA are likely safe but can raise estrogen levels slightly for a time, and there's more concern for women on aromatase inhibitors.
What does the research say about vaginal estrogen and breast cancer?
A 2024 study in JAMA Oncology followed more than 49,000 women diagnosed with breast cancer in Scotland and Wales and found no increase in breast cancer deaths among those who used vaginal estrogen. It was an observational study, not a randomized trial, so it can't settle the question for every woman.
What are the alternatives to vaginal estrogen after breast cancer?
ACOG says vaginal DHEA or testosterone may help with pain during sex if estrogen isn't an option, though NCCN presenters called vaginal testosterone controversial and something to discuss with your oncology team. They described vaginal laser treatment as still investigational.
Is menopausal hormone therapy safe after breast cancer?
Systemic hormone therapy, the pills and patches used for menopause, is different from low-dose vaginal estrogen. NCCN presenters said it is generally not recommended after breast cancer. It may be considered for severe hot flashes that nothing else has helped, decided together with your oncologist.
Questions to ask your oncologist about vaginal estrogen
- Is low-dose vaginal estrogen an option for me, given my cancer and my treatment?
- If not, why not, and what would you suggest instead?
- Does being on an aromatase inhibitor change the answer?
- Would vaginal DHEA be safer or less safe for me?
- How would we know if it was causing a problem?
More from Babette on sex after breast cancer
- Why Does Breast Cancer Treatment Change Your Sex Life?
- What Helps Vaginal Dryness After Breast Cancer?
- Why Does Sex Hurt After Breast Cancer?
- Where Did My Sex Drive Go After Breast Cancer?
- How Do You Talk About Sex After Breast Cancer?
- Is It Safe to Have Sex During Breast Cancer Treatment?
- Sex and Intimacy After Breast Cancer, by founder Jasmine Jones
Sources: American Cancer Society, Managing Sexual Side Effects as a Woman with Cancer (accessed October 2026); American College of Obstetricians and Gynecologists, Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-dependent Breast Cancer: Clinical Consensus, Obstetrics & Gynecology (December 2021), as summarized by Guideline Central; Ballinger, Reese and Ratner, Issues with Sexuality and Sexual Function in Patients with Breast Cancer, National Comprehensive Cancer Network 2024 Breast Cancer Congress (February 2, 2024); McVicker et al., Vaginal Estrogen Therapy Use and Survival in Females With Breast Cancer, JAMA Oncology (January 2024). This article is general information, written in Babette's own words, and is not a substitute for advice from your care team.
